Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.

Lind, Joline S W

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. [electronic resource] - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Dec 2009 - 1585-6 p. digital

Publication Type: Case Reports; Journal Article

1556-1380

10.1097/JTO.0b013e3181bbb2b9 doi


Carcinoma, Non-Small-Cell Lung--drug therapy
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride
Female
Humans
Lung Neoplasms--drug therapy
Middle Aged
Mutation--genetics
Neoplasm Recurrence, Local--drug therapy
Prognosis
Protein Kinase Inhibitors--administration & dosage
Quinazolines--administration & dosage
Skin Diseases--chemically induced